U.S. markets open in 7 hours 14 minutes
  • S&P Futures

    4,170.00
    -5.75 (-0.14%)
     
  • Dow Futures

    34,160.00
    -46.00 (-0.13%)
     
  • Nasdaq Futures

    12,767.75
    -9.00 (-0.07%)
     
  • Russell 2000 Futures

    1,974.70
    -4.60 (-0.23%)
     
  • Crude Oil

    77.31
    +0.17 (+0.22%)
     
  • Gold

    1,875.50
    +3.80 (+0.20%)
     
  • Silver

    22.32
    +0.14 (+0.64%)
     
  • EUR/USD

    1.0733
    +0.0002 (+0.02%)
     
  • 10-Yr Bond

    3.6740
    0.0000 (0.00%)
     
  • Vix

    18.66
    -0.77 (-3.96%)
     
  • GBP/USD

    1.2047
    -0.0005 (-0.04%)
     
  • USD/JPY

    131.3000
    +0.2280 (+0.17%)
     
  • BTC-USD

    23,208.47
    +259.77 (+1.13%)
     
  • CMC Crypto 200

    535.93
    +9.98 (+1.90%)
     
  • FTSE 100

    7,864.71
    +28.00 (+0.36%)
     
  • Nikkei 225

    27,606.46
    -79.01 (-0.29%)
     

Corbus Pharmaceuticals to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference

NORWOOD, Mass., Sept. 12, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference.   The hybrid conference will take place September 12-14, 2022.

Corbus Pharmaceuticals Logo (PRNewsfoto/Corbus Pharmaceuticals Holdings, Inc.)
Corbus Pharmaceuticals Logo (PRNewsfoto/Corbus Pharmaceuticals Holdings, Inc.)

A livestream of the virtual presentation is available on-demand beginning today, Monday, September 12, 2022 at 7:00 AM ET for those who are registered to attend the conference and will be accessible for 30 days on the H.C. Wainwright conference platform. For more information, please visit the conference website.

About Corbus

Corbus is an immunology company committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways.  Corbus' current pipeline includes anti-integrin monoclonal antibodies that block activation of TGFβ and small molecules that activate or inhibit the endocannabinoid system. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on Twitter, LinkedIn and Facebook.

INVESTOR CONTACT:
Sean Moran
smoran@corbuspharma.com

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/corbus-pharmaceuticals-to-present-virtually-at-the-hc-wainwright-24th-annual-global-investment-conference-301621611.html

SOURCE Corbus Pharmaceuticals